CN117355312A - 治疗cns和全身性疾病的line-1抑制剂 - Google Patents

治疗cns和全身性疾病的line-1抑制剂 Download PDF

Info

Publication number
CN117355312A
CN117355312A CN202280034771.5A CN202280034771A CN117355312A CN 117355312 A CN117355312 A CN 117355312A CN 202280034771 A CN202280034771 A CN 202280034771A CN 117355312 A CN117355312 A CN 117355312A
Authority
CN
China
Prior art keywords
line
inhibitor
disease
subject
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280034771.5A
Other languages
English (en)
Chinese (zh)
Inventor
E·韦伯
M·G·科丁利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transposition Therapy Co ltd
Original Assignee
Transposition Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transposition Therapy Co ltd filed Critical Transposition Therapy Co ltd
Publication of CN117355312A publication Critical patent/CN117355312A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
CN202280034771.5A 2021-03-15 2022-03-15 治疗cns和全身性疾病的line-1抑制剂 Pending CN117355312A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163161050P 2021-03-15 2021-03-15
US63/161,050 2021-03-15
PCT/US2022/020362 WO2022197689A1 (en) 2021-03-15 2022-03-15 Line-1 inhibitors to treat cns and systemic diseases

Publications (1)

Publication Number Publication Date
CN117355312A true CN117355312A (zh) 2024-01-05

Family

ID=83321069

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280034771.5A Pending CN117355312A (zh) 2021-03-15 2022-03-15 治疗cns和全身性疾病的line-1抑制剂

Country Status (15)

Country Link
US (1) US20240173346A1 (https=)
EP (1) EP4308237A4 (https=)
JP (1) JP2024511973A (https=)
KR (1) KR20230157430A (https=)
CN (1) CN117355312A (https=)
AU (1) AU2022237405A1 (https=)
BR (1) BR112023018714A2 (https=)
CA (1) CA3211369A1 (https=)
CL (1) CL2023002746A1 (https=)
DO (1) DOP2023000192A (https=)
IL (1) IL305869A (https=)
MA (1) MA62910A1 (https=)
MX (1) MX2023010657A (https=)
UA (1) UA130707C2 (https=)
WO (1) WO2022197689A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
WO2021102423A1 (en) 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US20250170158A1 (en) * 2022-02-22 2025-05-29 Rome Therapeutics, Inc. Methods of treating medical conditions using censavudine or a related compound
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
WO2023178128A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Methods of treating medical conditions using islatravir or a related compound
CA3246792A1 (en) * 2022-03-30 2023-10-05 Transposon Therapeutics, Inc. NUCLEOSIDE LINE-1 INHIBITORS
WO2024129788A1 (en) * 2022-12-13 2024-06-20 Brown University Small molecule inhibitors of the line-1 endonuclease domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535045T3 (es) * 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
EP2965760A1 (en) * 2014-07-09 2016-01-13 Université de Montpellier Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases
CN105012305A (zh) * 2015-07-24 2015-11-04 福建广生堂药业股份有限公司 拉米夫定及其药用盐治疗老年性黄斑部病变的用途
RU2726210C2 (ru) * 2018-12-27 2020-07-09 Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" Комбинация противовирусных средств, набор и способ лечения на ее основе
EP3914604B1 (en) * 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
TW202104210A (zh) * 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑

Also Published As

Publication number Publication date
AU2022237405A1 (en) 2023-11-02
UA130707C2 (uk) 2026-04-22
WO2022197689A1 (en) 2022-09-22
KR20230157430A (ko) 2023-11-16
MA62910A1 (fr) 2023-12-29
EP4308237A1 (en) 2024-01-24
DOP2023000192A (es) 2024-02-29
CL2023002746A1 (es) 2024-04-05
EP4308237A4 (en) 2025-03-05
US20240173346A1 (en) 2024-05-30
MX2023010657A (es) 2023-09-21
BR112023018714A2 (pt) 2023-10-24
IL305869A (en) 2023-11-01
CA3211369A1 (en) 2022-09-22
JP2024511973A (ja) 2024-03-18

Similar Documents

Publication Publication Date Title
CN117355312A (zh) 治疗cns和全身性疾病的line-1抑制剂
ES2688925T3 (es) Tratamiento antiviral
DE60025385T2 (de) 2,4-diaminopyrimidinderivate als immunosuppressiva
KR20240017910A (ko) 인지 향상제로서 line-1 억제제
US20200246331A1 (en) Pharmaceutical combinations and their use
EP1113802B1 (en) Antiviral combinations of lamivudine and adefovir
ES2280259T3 (es) Complejos de galio de 3-hidroxi-4-pironas para tratar infecciones por procariotas intracelulares, virus de adn y retrovirus.
US8513280B2 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
WO2014201426A2 (en) Triazol-1-ol analogs anti-retroviral latency drugs
JP2002534390A (ja) 癌治療におけるアデノシンアゴニスト類の使用
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US6432966B2 (en) Antiviral combinations
OA21831A (en) LINE-1 inhibitors to treat CNS and systemic diseases.
ES2309222T3 (es) Inhibidores no nucleosidos de la transcriptasa inversa como antagonistas de la proliferacion celular e inductores de la diferenciacion celular.
US20150104416A1 (en) Leukemic Stem Cell Ablation
EA001457B1 (ru) Комбинации, содержащие vx478, зидовудин и/или 1592u89, для применения при лечении вич
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
RU2316320C1 (ru) Противовирусное средство
KR20070114806A (ko) 바이러스 감염 치료에의 티오포스포노포름산 및 ｎｒｔｉ의용도
MXPA01002673A (en) Antiviral combinations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination